SAVA
Cassava Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +32.7%
- EBIT
- +32.6%
- EPS
- —
- Free cash flow
- +71.9%
- Operating cash flow
- +72.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +33.1%
- EBIT
- +32.6%
- Net income
- —
- EPS
- —
- Free cash flow
- +71.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025